Report overview
Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin.?
This report contains market size and forecasts of Hemoglobinopathy Drugs in Global, including the following market information:
Global Hemoglobinopathy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hemoglobinopathy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hydroxyurea Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hemoglobinopathy Drugs include Novartis, AstraZeneca, Bluebird, Bristol-Myers Squibb, Emmaus Medical, Acceleron Pharma, HemaQuest Pharmaceuticals, Eli Lilly and Company and Celgene. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemoglobinopathy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemoglobinopathy Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hemoglobinopathy Drugs Market Segment Percentages, by Type, 2021 (%)
Hydroxyurea
Glutamine
Zynteglo
Other
Global Hemoglobinopathy Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hemoglobinopathy Drugs Market Segment Percentages, by Application, 2021 (%)
Sickle Cell Diseases
Thalassemia
Global Hemoglobinopathy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hemoglobinopathy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemoglobinopathy Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hemoglobinopathy Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
AstraZeneca
Bluebird
Bristol-Myers Squibb
Emmaus Medical
Acceleron Pharma
HemaQuest Pharmaceuticals
Eli Lilly and Company
Celgene
